ORABASE HCA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORABASE HCA (ORABASE HCA).
Hydrocortisone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing prostaglandin and leukotriene synthesis, thereby suppressing inflammation. Orabase (hydroxypropyl cellulose) forms a protective barrier over oral lesions.
| Metabolism | Hydrocortisone is metabolized primarily in the liver via 11β-hydroxysteroid dehydrogenase; minor metabolism by CYP3A4. Orabase is not metabolized. |
| Excretion | Primarily renal elimination of metabolites; <5% excreted unchanged. Biliary/fecal excretion accounts for a minor fraction. |
| Half-life | Plasma half-life approximately 1-2 hours for hydrocortisone; clinical effects persist longer due to local tissue retention. |
| Protein binding | Hydrocortisone is ~75-85% bound to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | Vd for hydrocortisone is approximately 0.3-0.5 L/kg, indicating distribution into total body water. |
| Bioavailability | Topical: systemic absorption is minimal (<5%) through intact oral mucosa; inflamed mucosa may increase absorption. |
| Onset of Action | Topical: relief within minutes to hours; depends on formulation and condition. |
| Duration of Action | Topical: effects last 2-4 hours; dental paste provides prolonged contact up to 2 hours. |
Apply a small amount (approximately 2.5 cm) to the affected area as a thin film 2-3 times daily, after meals and at bedtime. Do not rub in. For adults, maximum duration of use is 7 days unless directed by a physician.
| Dosage form | PASTE |
| Renal impairment | No dose adjustment required for renal impairment as systemic absorption is minimal with topical application. |
| Liver impairment | No dose adjustment required for hepatic impairment as systemic absorption is minimal with topical application. |
| Pediatric use | Children <12 years: Safety and efficacy not established; use only under physician supervision. Children ≥12 years: Same as adult dosing; apply a small amount (approximately 2.5 cm) 2-3 times daily. |
| Geriatric use | No specific dose adjustment required; use same as adult dosing. Caution in elderly due to potential for mucosal atrophy with prolonged use; limit duration to short-term (≤7 days). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ORABASE HCA (ORABASE HCA).
| Breastfeeding | Not known if hydrocortisone is excreted in breast milk after topical application; however, systemic absorption is minimal with short-term use. M/P ratio not established. Caution advised, use only if clearly needed. |
| Teratogenic Risk | Topical corticosteroids are generally considered low risk for teratogenicity when used in limited amounts; however, systemic absorption can occur. Animal studies with corticosteroids have shown teratogenicity, but no adequate human studies for ORABASE HCA. Use only if benefit outweighs risk; avoid prolonged use, especially in first trimester. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to hydrocortisone or any component of Orabase","Untreated fungal, viral, or bacterial oral infections","Perioral dermatitis"]
| Precautions | ["Prolonged use may lead to oral candidiasis","Immunosuppression may mask infections","Systemic absorption possible with extensive application","Avoid use in presence of untreated oral infections"] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of hypothalamic-pituitary-adrenal (HPA) axis suppression in mother if used long-term or on large areas. No specific fetal monitoring required with short-term topical use. |
| Fertility Effects | No known effects on fertility with topical use. Systemic corticosteroids may affect fertility, but topical application in oral doses is unlikely to have significant impact. |